Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class
After Losing 23% in the Past Year, Foghorn Therapeutics Inc. (NASDAQ:FHTX) Institutional Owners Must Be Relieved by the Recent Gain
Express News | Foghorn Therapeutics Says Flagship Pioneering Raised $3.6B To To Support The Creation And Development Of An Estimated 25 Breakthrough Companies In Human Health
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations That Transform Human Health and Sustainability
Flagship Pioneering Expands Leadership Team With Key Appointments and Promotions
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
Foghorn Therapeutics Raises ~$110 Million Through Direct Offering
Express News | Foghorn Therapeutics Inc.: Extends Cash Runway Into 2027
Express News | Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Foghorn Prices $110M Mixed-shelf Registered Direct Offering
Express News | Foghorn Therapeutics Inc. - Sees Total Gross Proceeds From Offering Will Be Approximately $110 Mln
Express News | Foghorn Therapeutics Inc. - Pricing of a Registered Direct Offering of 12.7 Mln Shares of Its Common Stock at a Price of $5.51 per Share
Express News | Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
Investors Don't See Light At End Of Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Tunnel And Push Stock Down 25%
Express News | Flagship Pioneering- $600 Mln in Payments From Novo Nordisk, to Be Shared Between Metaphore, Pioneering Medicines
Express News | Flagship Pioneering-Upto $600 Mln in Upfront, Development,Commercial Milestone Payments, Tiered Royalties on Annual Net Sales of Products From Novo
Express News | Flagship Pioneering Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...